drugset / Trial / NCT00012155

Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver

NCT00012155 ↗

Treatment

Summary

RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that has spread to the liver and has not responded to previous chemotherapy.

Timeline

Start
2000-10
Primary completion
2002-11
Completion
2009-12

Publications

  • Results Kemeny N, Jarnagin W, Guilfoyle B, et al.: Results of a phase I, dose-escalating study of the safety, tolerability and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, nv1020, in subjects with hepatic colorectal metastases. [Abstract] Ann Oncol 16 (Suppl 2): A-480, ii283, 2005.

Drugs

EvaluationDrugModalityDoseRoute
Subject NV1020 Unknown — Other